Learn more about Peter Attia’s digital program
#279 – AMA #53: Metabolic health & pharmacologic interventions: SGLT-2 inhibitors, metformin, GLP-1 agonists, and the impact of statins
“It is worth noting, and this is a very important question, that it does not appear that the effect of statins on insulin resistance is a function of lipids being lowered.” —Peter Attia
#276 ‒ Special episode: Peter answers questions on longevity, supplements, protein, fasting, apoB, statins, and more
“One of the most important things to understand when you are using some sort of intervention is, do you have a biomarker to know if you’re doing it correctly?” —Peter Attia
Statins: effectiveness, safety, and common myths on their role in ASCVD prevention
A review of the evidence for statins in combating heart disease
A new analysis of REDUCE-IT: benefits of omega-3s vs. harm from placebos
A secondary analysis of biomarker data from REDUCE-IT raises questions about the apparent benefits of EPA-derivative icosapent ethyl
#231 – AMA #41: Medicine 3.0, developments in the field of aging, healthy habits in times of stress, and more
“We have reached the limits of medicine 2.0 capacity, and if longevity is something we are aspiring for, we need a new strategy.” —Peter Attia
#230 ‒ Cardiovascular disease in women: prevention, risk factors, lipids, and more | Erin Michos, M.D.
“How we live the first half of our lives really influences our freedom for morbidity and mortality the second half of our lives.” —Erin Michos
Reassuring new data on statin-induced Lp(a) elevation
Statin therapy is known to raise Lp(a) particle concentration in some patients, but how does this impact the overall effect of these medications on ASCVD risk?
Why a recent study hasn’t shaken my faith in statins
A rebuttal of Byrne et al.
Low LDL cholesterol and neural development
Why LDL-lowering treatments don’t pit head against heart
Does low cholesterol cause cognitive impairment? Part II
Safety of lipid-lowering therapy